ReviewWIREs mechanisms of disease2021
Liver fibrosis: Pathophysiology and clinical implications.
Review in WIREs mechanisms of disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 2 syntheses or guidelines pooled it, 235 citations in OpenAlex.
- The Impact of the Alternate Mediterranean Diet (aMED) on the Prevention of Chronic Liver Disease: A Meta-Analysis of Observational Studies.Nutrients · 2025Pooled it
- Mesenchymal stem cell therapy for liver fibrosis need "partner": Results based on a meta-analysis of preclinical studies.World journal of gastroenterology · 2024Pooled it
- Visnagin Attenuates Thioacetamide-Induced Liver Injury and Fibrosis Through the Modulation of TLR4-Mediated Inflammation and Downregulation of TGF-β/α-SMA-Driven Fibrogenesis.Journal of applied toxicology : JAT · 2026Article
- HBV/HCV coinfection and anti-tuberculosis drug-induced liver injury: from risk assessment and exploration of mechanisms to preventive considerations.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Decoding Tumor-Immune Interactions in Hepatocellular Carcinoma Through Network-Centered Identification of CXCR2.International journal of molecular sciences · 2026Article
- Taohong Huazhuo decoction alleviates carbon tetrachloride-induced hepatic fibrosis in rats by inhibiting the nicotinamide adenine dinucleotide phosphate oxidase 4/nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 signaling pathway.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Article
- Hepatitis Viruses Infection Up-Regulating Fibrosis Signals in Hepatocellular Carcinoma.Biomedicines · 2026Article
- Integrative Medicine for Liver Fibrosis: Bioactive Constituents and Therapeutic Potential of Scutellaria baicalensis.Chinese journal of integrative medicine · 2026Review
- Liver Fibrosis and Purinergic Signaling: Autocrine-Paracrine Role of ATP in Liver Damage.International journal of molecular sciences · 2026Review
- [Scientific reports · 2026Article
- An integrated strategy for screening Q-markers and elucidating anti-fibrotic mechanisms of Ganoderma lucidum.BMC complementary medicine and therapies · 2026Article
- Mechanisms and reversal strategies of liver fibrosis: from regulation of cell fate to clinical translation.Journal of translational medicine · 2026Review
- Dual Modulation of Senescence and Immune Checkpoints by Metformin and Dapagliflozin Attenuates Liver Fibrosis in a Thioacetamide-Induced Rat Model.Advanced pharmaceutical bulletin · 2026Article
- Role and clinical importance of lactylation in tumors (Review).Molecular medicine reports · 2026Review
- Synthesis and application of encapsulated Bifidobacterium Longum for mitigation of liver fibrosis via modulation of oxidative stress and inflammation in BDL rat model.World journal of microbiology & biotechnology · 2026Article
- MRI Quantification of Liver Fibrosis Using Diamagnetic Susceptibility: An Ex Vivo Validation Study.Tomography (Ann Arbor, Mich.) · 2026Article
- Green-Synthesized Rutin-Capped Gold Nanoparticles Attenuate Experimental Liver Fibrosis by Targeting Oxidative Stress and TGF-β Signaling.Nanomaterials (Basel, Switzerland) · 2026Article
- The Extracellular Matrix in Liver Regeneration: Biological and Therapeutic Insights.Bioengineering (Basel, Switzerland) · 2026Review
- Autophagy-mediated Kupffer cell polarization in liver cirrhosis reversal: Mechanistic insights and therapeutic strategies.Liver research (Beijing, China) · 2026Review
- Development of a hybrid deep learning-based framework for liver fibrosis classification using ultrasound images.iLIVER · 2026Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Liver fibrosis is a clinically significant finding that has major impacts on patient morbidity and mortality. The mechanism of fibrosis involves many different cellular pathways, but the major cell type involved appears to be hepatic stellate cells. Many liver diseases, including Hepatitis B, C, and fatty liver disease cause ongoing hepatocellular damage leading to liver fibrosis. No matter the cause of liver disease, liver-related mortality increases exponentially with increasing fibrosis. The progression to cirrhosis brings more dramatic mortality and higher incidence of hepatocellular carcinoma. Fibrosis can also affect outcomes following liver transplantation in adult and pediatric patients and require retransplantation. Drugs exist to treat Hepatitis B and C that reverse fibrosis in patients with those viral diseases, but there are currently no therapies to directly treat liver fibrosis. Several mouse models of chronic liver diseases have been successfully reversed using novel drug targets with current therapies focusing mostly on prevention of myofibroblast activation. Further research in these areas could lead to development of drugs to treat fibrosis, which will have invaluable impact on patient survival. This article is categorized under: Metabolic Diseases > Molecular and Cellular Physiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.